BALTIMORE, March 25, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the appointment of Sanjin Zvonić, PhD, as Vice President of Process Science and Manufacturing. In this role, Dr. Zvonić will oversee manufacturing for all of WindMIL’s cell therapies, ensuring the company supplies product to meet the demands of several upcoming clinical studies, and ultimately, position WindMIL therapeutic candidates for commercialization.

“Sanjin brings to WindMIL more than 15 years of experience in the development and manufacturing of cell-based therapeutics, with an impressive scientific and technical background in physiology, stem cell biology, and cell therapy CMC development. At WindMIL, we’re always looking to the future of cancer immunotherapy, so Sanjin’s ability to bridge research and manufacturing makes him an ideal fit for us as we deliver both the current generation of MILs™ and look toward developing the next generation,” said Don Hayden, Interim CEO and Executive Chairman of WindMIL Therapeutics. “We are also fortunate that Sanjin is very focused on people development. Having him join WindMIL during this time of growth will help ensure we develop the team to its greatest potential.”

Prior to joining WindMIL, Dr. Zvonić served as Senior Director and Business Leader of Clinical and Commercial Manufacturing at Hitachi Chemical Advanced Therapeutics Solutions (HCATS), LLC, as Progenitor Cell Therapy (PCT) integrated into Hitachi. There, he focused on driving the growth and development of PCT's clinical and commercial manufacturing business lines and facilitating the company’s integration. He had previously served at PCT from 2009 to 2014, first as Director of Technology and Business Development and later as Director of Technology Applications, during which time he focused on client engagement and technology transfer. From 2014 through 2016, Dr. Zvonić was a Senior Fellow in Novartis’ Cell and Gene Therapies Unit, where he worked on the development and commercialization of Novartis cell and gene therapy pipeline products. He received his doctorates in Cell and Molecular Biology and in Human Nutrition from Louisiana State University, after which he moved on to translational research-focused post-doctoral fellowships at Pennington Biomedical Research Center and Tulane University.

“I’m honored to join the WindMIL team as we continue to grow and find new ways to translate novel insights in bone marrow immunology into our MILs™ technology platform, creating life-saving cell therapies for cancer patients,” said Dr. Zvonić. “It’s an exciting time to join such a ground-breaking company.”

About WindMIL Therapeutics
WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow infiltrating lymphocytes (MILs™) for cancer immunotherapy. As the leader in cellular therapeutics emanating from bone marrow, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients. The company’s proprietary process to extract, activate and expand these cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxic potential, and long persistence. For more information, please visit: https://windmiltherapeutics.com.

Media Contact:

Tony Plohoros
6 Degrees
(908) 940-0135
tplohoros@6degreespr.com  

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0ddbc1d4-37e7-4527-b36e-d675843caad3